Vera V. Shadrina

Vera V. Shadrina

Auto-generated profile, based on publicly available information

Vera V. Shadrina

Research Clinical Institute of Childhood of the Moscow Region

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Genes
Verified
Journal Article
Open access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
TBTatiana Bukharova
Tatiana Bukharova
AEAnna Efremova
Anna Efremova
YMYuliya Melyanovskaya
Yuliya Melyanovskaya
NBNatalia Bulatenko
Natalia Bulatenko
DGDmitry Goldshtein
Dmitry Goldshtein
Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease, associated with pathogenic variants in the CFTR gene. The splicing variant c.3140-16T>A (3272-16T>A) has been described previously and, according to the Russian CF Patients Registry, occurs with a frequency of 0.34%. The phenotypic features of CF patients with the c.3140-16T>A variant were compared with those of patients with the genotype F508del/F508del. Patients with the allele c.3140-16T>A had higher average age and age at diagnosis, and the allele was present in a greater proportion of adults. Patients carrying the c.3140-16T>A allele were characterised by better physical development indicators, both in adults and in children, had preserved pancreatic function, as well as the absence of a number of complications, and required pancreatic enzyme replacement therapy less often than patients with the F508del/F508del genotype. Sweat test values also were lower in patients with the c.3140-16T>A genotype. According to the results of clinical and laboratory studies, the phenotype of patients with the genetic variant c.3140-16T>A can be considered “mild”. Functional CFTR protein activity in the presence of c.3140-16T>A was evaluated using intestinal current measurements (ICM) and the forskolin-induced swelling assay on organoids obtained from patients’ rectal biopsies. c.3140-16T>A had high residual CFTR channel activity and was amenable to effective pharmacological correction with thea VX-770 potentiator. To evaluate the effect of the variant on CFTR pre-mRNA splicing we performed a minigene assay, as well as RT-PCR analysis of RNA isolated from the nasal epithelium and rectal biopsy of patients. We showed that the c.3140-16T>A variant creates a novel acceptor AG dinucleotide within CFTR intron 19, resulting in a 14-nucleotide extension of exon 20. This frameshift produces a premature termination codon and triggers mRNA degradation by the nonsense-mediated decay (NMD) mechanism. Moreover, we observed that the c.3140-16T>A allele could produce a residual amount of normally spliced transcript, thus explaining the patient’s mild phenotype.

27 May 2022 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
ABAlexander A. Baranov
Alexander A. Baranov
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
SKSergei I. Kutsev
Sergei I. Kutsev
SASergey Avdeev
Sergey Avdeev
EPElena V. Polevichenko
Elena V. Polevichenko
ЭСЭ. В. Синьков
Э. В. Синьков
The problem of timely diagnosis and proper management of patients with cystic fibrosis is crucial not only in our country, but throughout the world. Experts of the Union of Pediatricians of Russia have considered various issues of etiology, pathogenesis, epidemiology, diagnosis, and treatment of this genetic disease in a modern light. Particular attention was paid to screening methods for early diagnosis of cystic fibrosis. The principles of complex therapy were justified, including rational use of antibacterial and mucolytic drugs and enzyme replacement therapy that significantly determine the disease prognosis.

11 April 2021 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
VSV. V. Shadrina
V. V. Shadrina
AVAnna Voronkova
Anna Voronkova
MSM. A. Starinova
M. A. Starinova
OSO. I. Simonova
O. I. Simonova
DSD. F. Sergienko
D. F. Sergienko
НКН. Ю. Каширская
Н. Ю. Каширская
Identifying the initial manifestations of pulmonary functional disorders associated with cystic fibrosis (CF) is essential for timely correction of the therapy and improvement of the prognosis.The aim of the study was to identify the age periods with the highest risk of a decrease in lung function in children with different CF genotypes.Methods. Lung function (LF) was analyzed using spirometry results in CF patients aged 6 to 18 years from the Registry of patients with cystic fibrosis in the Russian Federation 2018.Results. The forced expiratory volume in one second (FEV1) was statistically significantly lower in children aged 6 – 10 years with “severe” genotypes than in the children with “mild” genotypes. The lung function was reduced at 11 – 14 years of age in both “severe» and “mild” genotypes without any statistically significant difference. In general, the trend of a decrease in lung function in “severe” genotypes persists in the adolescent period from 15 to 18 years. The lung function is better in adolescents aged 15 – 18 with the “mild” variants of genotypes compared to the patients aged 11 – 14 years.Conclusion. The “severe” variants of CFTR negatively affect LF of CF patients in all age groups. The LF values in patients with “mild” genotypes at the age of 15 – 18 years were higher than in children aged 11 – 14 years with the same genotypes. There is a need for improved programs of medical care for adolescents with CF.

17 July 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
VSV. V. Shadrina
V. V. Shadrina
EZElena Zhekaite
Elena Zhekaite
AVAnna Voronkova
Anna Voronkova
VSVictoria Sherman
Victoria Sherman
YKYu. A. Kondakova
Yu. A. Kondakova
EKElena Kondatyeva
Elena Kondatyeva
Mannitol for inhalation is recommended for the treatment of cystic fibrosis in children over 6 years of age and adults. Because of the risk of bronchospasm, a challenge test to assess the drug tolerability should be performed prior to prescribing inhalation mannitol. Aim. Tо evaluate the tolerability of the first dose of inhaled mannitol in children with cystic fibrosis. Methods. The mannitol challenge test (according to the instructions for use of the Bronchitol (inhaled mannitol), Pharmaxis Ltd, Australia) was assessed in 81 children aged 6 to 18 years (11.6 ± 3.2 years). The patients were observed in the centers of the Novosibirsk region, the Moscow region, and the Perm region. The patient’s general state, forced expiratory volume in the first second (FEV1), and SpO2 were monitored. Results. Baseline FEV1 data in patients ranged from 30 % to 146 % (87.8 ± 25.7%), and SpO2 was 94 – 99% (97.7 ± 1.3%). 73 (90.1%) patients passed the test. In 8 (9.9%) patients, the following symptoms were observed: bronchospasm (6), laryngospasm (1), and vomiting (1). Bronchial obstruction was treated by inhalation of a bronchodilator, and the children were under observation until the restoration of FEV1. In patients who passed the test, FEV1 ranged from 33 to 149 % (85.4 ± 24.5%), and SpO2 spanned from 95 to 99% (96.7 ± 1.7%). The children who did not pass the test were monitored. One patient passed the test later when targeted therapy was added. Two children did not tolerate other mucolytic drugs (one child – NaCl solution in various dilutions, and the second patient suffering from asthma – dornase alfa). During follow-up, one patient was diagnosed with allergic bronchopulmonary aspergillosis at 12 years of age and with asthma at 13 years of age, which may have influenced the decrease in mannitol tolerability through formation of bronchial hyperreactivity. Thus, true adverse drug reaction in the form of bronchospasm occurred in three children out of 81 (3.7%). Conclusion. 90.1% of patients passed the inhalation mannitol challenge test, and 9.9% of patients did not pass the test. Analysis of adverse drug reactions revealed that only 3.7% of patients experienced true adverse reactions in the form of bronchospasm. During the test, patients were taught the correct technique for inhaling the drug. All the supplies to relieve bronchospasm should be readily available during the test.

28 May 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
EKElena Kondatyeva
Elena Kondatyeva
VSV.V. Shadrina
V.V. Shadrina
EFE.G. Furman
E.G. Furman
AVAnna Voronkova
Anna Voronkova
VSVictoria Sherman
Victoria Sherman
VHVolgograd Volgograd Children'S Clinical Hospital
Volgograd Volgograd Children'S Clinical Hospital
The aim of the program was to study the tolerability of Tigerase® in patients with cystic fibrosis (CF) of all ages in rutine clinical practice. Study design: retrospective open uncontrolled comparative multicenter solid. Materials and methods of research: retrospective data of clinical observations were collected from medical records of patients with CF on the use of Tigerase®. Results: therapy with Tigerase® was well tolerated by 668 (93,4%) of 715 patients included in the study. In 47 (6,6%) patients, 127 adverse reactions (ADRs) associated with the use of Tigerase® were recorded. ADRs from the respiratory system were the most common. Of these, 24 (3,4%) were coughing and 10 (1,4%) had increased viscosity of bronchial secretion. Among all patients included in the study, the proportion of patients in whom ADRs were registered based on clinical manifestations (3,9%) did not differ statistically significantly from the proportion of patients in whom ADRs were recorded based on complaints only (2,8%) (p=0,30). The distribution of ADRs by the source of registration and place of residence of patients did not depend on their gender and age. Registration of ADRs in different regions of the country differed statistically significantly both in frequency and in the source of detection (p<0,001). ADRs were not recorded in several regions, and the largest number of ADRs were registered in patients living in Moscow, and most of them were based only on patient complaints. 22 patients (47% of the number of patients with ADR) had medical commissions for ADR, and only in 8 (17% of the number of patients with ADR) of them had expertise of specialists with experience in the treatment of patients with CF. In 29 patients (62% of the number of patients with ADR), the development of ADR did not require cessation of the Tigerase® therapy. Conclusion: in the majority of CF patients (93,4%) tolerated the Tigerase® therapy well.

11 March 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
VSV. V. Shadrina
V. V. Shadrina
EKElena Kondatyeva
Elena Kondatyeva
AVAnna Voronkova
Anna Voronkova
EZElena Zhekaite
Elena Zhekaite
SKS. A. Krasovskiy
S. A. Krasovskiy
AVA. V. Vlasova
A. V. Vlasova
The article discusses results of a prospective observational study of long-term use of the biosimilar dornase alfa (Tigerase) (Generium, Russia) as part of complex therapy in patients with cystic fibrosis in real clinical practice.The aim was to analyze the outcomes of long-term use of the dornase alfa dornase alfa as part of complex therapy in patients with CF (protocol #DRN-CFR-N01).Methods. The study included patients (n = 165) aged 5 years and older from 11 centers for treatment of cystic fibrosis in the Russian Federation with a confirmed diagnosis of cystic fibrosis who were prescribed dornase alfa by their attending physician.Results. The analysis revealed that exacerbations of chronic pulmonary disease during the treatment with dornase alfa were observed in 29 (17.58%) patients included in the study. At the same time, there were no statistically significant changes in FEV1 and FVC (%) against baseline during the treatment in the study population. Adverse events related to the study drug were recorded in 9 (5.45%) patients.Conclusion. Biosimilar dornase alfa demonstrated a favorable efficacy and safety profile in routine clinical practice, which confirms the results of previously published studies.